BioMarin Cuts 117 California Roles in Footprint Consolidation

BioMarin Pharmaceutical is eliminating 117 positions across California as the rare-disease drugmaker consolidates its operational footprint, according to Fierce Pharma.

The San Rafael–based company develops enzyme-replacement and gene therapies for rare genetic conditions. The cuts were filed under California's Worker Adjustment and Retraining Notification (WARN) framework, which requires 60 days' advance written notice for mass separations and unlocks access to state-funded reemployment services.

What "consolidation" typically means here

Consolidation-driven reductions at biotechs usually take the form of site closures, the merger of duplicated functions, or shifts of work across geographies. The roles most often affected sit in commercial operations, manufacturing support, and administrative functions — though clinical and R&D positions sometimes fall inside the same notice when programs are paused or refactored.

BioMarin has not yet named which California sites are affected, which functions are being trimmed or whether the company is offering internal redeployment windows. Affected employees should expect formal separation terms — severance, benefits continuation, and the WARN-mandated transition package — within the 60-day notice clock.

A cooling market for mid-sized biotechs

The action lands against a labor market that has thinned noticeably for small and mid-cap drug developers since 2023. Capital remains tight, IPO windows have only partially reopened, and larger pharma partners are pushing patent-cliff pressure down into supplier pipelines. California still anchors the nation's largest biotech workforce, with concentrations in the San Francisco Bay Area, San Diego and greater Los Angeles — a depth of local employers that can absorb displaced workers but also concentrates the labor shock when a single regional player trims.

Where displaced specialists have landed

Recruiters working the California biotech corridor say demand has held up for regulatory affairs, clinical operations and bioprocess manufacturing talent — particularly candidates with cell-and-gene therapy exposure. Traditional discovery and early research roles have softened more sharply. Workers weighing offers should weigh severance math against the speed of placement: in California, the WARN clock runs alongside eligibility for Employment Development Department unemployment benefits and state-funded training vouchers.

What to watch next

Further consolidation details are likely to surface in BioMarin's next quarterly filing or earnings call, including one-time restructuring charges and any indication of additional site moves. Labor-market observers will read for whether the 117-headcount reduction is the leading edge of a broader reshuffle or a contained footprint adjustment.